NKTX Nkarta

Nkarta to Participate in an April Investor Conference

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

24th Annual Needham Virtual Healthcare Conference
April 8, 2025
11:00 a.m. ET – fireside chat
 
 

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Nadir Mahmood

Nkarta, Inc.



EN
01/04/2025

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in an April Investor Conference

Nkarta to Participate in an April Investor Conference SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat   A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is...

April 1, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and...

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash b...

March 26, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in March Investor Conferences

Nkarta to Participate in March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors section of Nkarta’s website, , and a re...

February 25, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myas...

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE N...

December 5, 2024 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in an Upcoming Investor Conference

Nkarta to Participate in an Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 7th Annual Evercore HealthCONx ConferenceDecember 4, 20242:10 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a c...

November 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch